Case Report

Benzylthiouracil-Induced Glomerulonephritis

Sihem Trimeche Ajmi,1 Rim Braham,1 Sarra Toumi,2 Molka Chadli Chaieb,1 Amel Maarouf,1 Koussay Ach,1 and Larbi Chaieb1

1 Department of Endocrinology, Farhat Hached Hospital, 4000 Sousse, Tunisia
2 Department of Internal Medicine, Sahloul Hospital, Sousse, Tunisia

Correspondence should be addressed to Sihem Trimeche Ajmi, sihem_t@yahoo.fr

Received 22 April 2009; Accepted 5 June 2009

Recommended by Shern L. Chew

Vasculitis is a rare complication of antithyroid drugs (ATDs). It was first described with Propylthiouracil (PTU). We report a new case of antineutrophil cytoplasmic antibody (ANCA) vasculitis with glomerulonephritis induced by Benzylthiouracil (BTU). A 50-year-old man with Graves disease treated with BTU developed general malaise and haematuria without skin rash or respiratory involvement. Laboratory data revealed acute renal failure with proteinuria and haematuria. An indirect immunofluorescence test for ANCA was positive, showing a perinuclear pattern with specificity antimumoperoxidase (MPO). A renal biopsy was performed and revealed pauci-immune extracapillary glomerular nephropathy and necrotic vasculitis lesions. Based on these findings we concluded to the diagnosis of rapidly progressive glomerulonephritis associated with ANCA induced by BTU therapy. The drug was therefore discontinued and the patient was treated with steroids and immunosuppressive treatment during 3 months. Renal failure, proteinuria and haematuria significantly improved within 2 months. However, P-ANCA remained positive until 10 months after drug withdrawal. Thyroid function was kept within normal range using iodine solution. We demonstrated clearly that BTU may induce severe forms of vasculitis with glomerulonephritis. Thus, the ANCA must be measured when confronted to systemic manifestation during treatment.

Copyright © 2009 Sihem Trimeche Ajmi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Antithyroid drugs (ATDs) such as Propylthiouracil (PTU) and Benzylthiouracil (BTU) are widely used for treatment of Graves disease. Commonly adverse effects related to the use of antithyroid drugs include agranulocytosis, cutaneous macular or papular skin rash, toxic hepatitis and induced lupus-like syndrome [1, 2]. ANCA positive vasculitis is a rare and severe complication of this treatment, described firstly with PTU [3], than with other ATD such as Carbimazole, Methimazole and recently Benzylthiouracil [4]. We report here a new case of Benzylthiouracil-induced ANCA positive vasculitis resulting in a necrotizing or crescentic glomerulonephritis.

2. Case Report

A 50-year-old man was admitted to the hospital because of general malaise and haematuria. He has a history of Graves disease diagnosed in 2004 and treated with Benzylthiouracile (Basdène) 300 mg/d for 8 months. On admission, his blood pressure was 120/70 mmHg and his pulse was regular at 108/min with no fever. On physical examination, the patient looked pale and his conjunctivas were anaemic. His thyroid gland was enlarged and there were no exophthalmia, skin rash or edema in lower extremities. Cardiovascular examination was normal.

Urine analysis showed haematuria (4+) and proteinuria (2+). Laboratory data at admission showed: hemoglobin 9.4 g/dL, serum urea 19.7 mmol/L (normal range: 2.5–7.5 mmol/L ), serum creatinine 413 μmol/L (normal range: 70–130 μmol/L); it was 54 μmol/L 8 months before, Proteinuria 1.1 g/d, haematuria 800 000 red blood cells/mL, erythrocyte sedimentation rate 102 at 1 hour. Serum concentrations of CH50, C3 and C4 were in normal range. Thyroid function was normal with negative antithyroglobulin (anti-TG), antiperoxydase (anti-TPO) antibodies, and positive antithyrotropin receptor antibodies (TRAb)
Benzylthiouracil, have been reported in literature \[5–8\]. In this paper we reported a new case of BTU-induced vasculitis. Crescentic glomerulonephritis associated with ANCA induced by BTU therapy was strongly suggested. The drug was therefore discontinued and patient was treated with pulse of methyl prednisolone (500 mg/d for 3 days) followed by oral prednisolone (60 mg/d) and monthly intravenous pulses of cyclophosphamide during 3 months. Renal failure, proteinuria and haematuria significantly improved within 2 months. Serum creatinine level decreased to 84 µmol/L and urine analysis revealed no proteinuria or haematuria. However, P-ANCA remained positive until 10 months after drug withdrawal. Thyroid function was kept within normal range using iodine solution.

3. Discussion

In this paper we reported a new case of BTU-induced ANCA positive vasculitis resulting in necrotizing glomerulonephritis. To our knowledge only four similar cases, with Benzylthiouracil, have been reported in literature \[5–8\]. ANCA vasculitis complicating antithyroid drugs was first reported in 1992 by Stankus and Johensen in a patient who developed severe respiratory failure with PTU \[3\]. In 1993, Dolman et al. reported the detection of ANCA in serum of six patients who developed vasculitis during PTU treatment of hyperthyroidism \[9\]. In these patients renal function was normal with no proteinuria. The ANCA are associated to systemic necrotizing vasculitis. The presenting symptoms of ATD induced ANCA vasculitis are variable including renal involvement, arthralgia, fever, skin involvement, respiratory tract involvement, myalgia or scleritis \[4\]. Our patient presented with clinical and biological disturbances related to renal failure with no medical history of pre-existing renal disease. Symptoms occurred 8 months after the beginning of treatment and there was no evidence of cutaneous vasculitis. ANCA positivity and renal biopsy which described pauci-immune extracapillary glomerular nephropathy concluded to the diagnosis of BTU induced vasculitis. Crescentic glomerulonephritis with ANCA positive vasculitis was firstly reported by Vogt in 1994, in 2 children receiving PTU \[10\]. Since then, many cases of ANCA positive vasculitis secondary to ATD have been described with mainly PTU \[11, 12\] and other ATD such as Carbimazole, Thiamazole \[13, 14\] and recently Benzylthiouracil \[5–8\]. Crescentic glomerulonephritis is histopathologically characterized by extracapillary proliferation and crescent formation in the majority of glomeruli with clinical syndrome of rapid deterioration in renal function occurring within few weeks or months \[15\]. Although immune complex was considered to be a possible cause of nephritis \[15\], its mechanism is still unknown. Griswold reported granular deposit of Immunoglobulin, complement in glomeruli on immunoﬂuorescence, and concluded that vasculitis secondary to PTU is an immune complex disease \[16\]. Besides, it is known that thyroid antigens have been implicated in the pathogenesis of glomerulonephritis \[17\]. However, in our case, there were no signiﬁcant deposit of immune complex and serum antithyroid antibodies (anti-TG and anti-TPO) were negative. This kind of pauci-immune nephritis is compatible with ANCA induced rapidly progressive glomerulonephritis as reported by Kudoh \[18\]. Graves disease is the most common underlying thyroid disease. ANCA positive vasculitis has been less frequently reported in association with toxic multinodular goiter \[19\]. Severe adverse effects secondary to ATD such as agranulocytosis usually occur within weeks after initiation of therapy \[20\]. However, ANCA positivity seems to be correlated to duration of therapy, the risk is particularly important after 18 months of treatment \[21\]. The clinical significance of ANCA positivity is still controversial. It has been reported that 20% of patients with hyperthyroidism taking PTU were serum ANCA positive during the course of therapy but a small number of them develop vasculitis \[9, 22\]. Dolman demonstrated clearly the role of PTU in vasculitis in 6 patients with vasculitis disorders which disappeared with concomitant fall in ANCA titers after withdrawal of PTU \[9\]. The pathogenesis of ANCA mediated vasculitis is not well understood. It seems that Thionamide accumulates in neutrophils \[23\], binds to MPO inducing alteration of the cell structure \[24\] and then initiation of autoantibody formation. Falsely positive ANCA may be encountered in some patients without systemic manifestation of vasculitis. This phenomenon is explained by a cross reaction between antithyroid antibodies (anti-TRAb or anti-TG) and ANCA \[25\]. Approximately 90% of cases of ANCA positive vasculitis have occurred in association with PTU \[4\]. Only few cases of vasculitis induced by BTU have been reported in the literature involving principally the kidney and the respiratory tract \[6–8\]. In fact, the prevalence of PTU-treated patients is much higher than other antithyroid medication which is a matter of preference of each doctor and of availability of drugs. In Tunisia, all cases of ANCA-positive vasculitis described to date were secondary to BTU, which is the main ATD used in practice.

Treatment of ANCA positive vasculitis with renal involvement is controversial. After withdrawal of ATD, improvement of renal function was obtained in most reported cases \[26, 27\]. In the other cases, corticosteroid treatment and/or immunosuppressive treatment were given \[28, 29\]. Since renal involvement in ANCA positive vasculitis may be a cause of end-stage renal failure, our patient was treated with cyclophosphamide and prednisolone in addition to BTU withdrawal. Renal outcome was favorable but ANCA remained positive several months after withdrawal of BTU. Discontinuing ATD does not always result in fall in titer or disappearance of circulating ANCA. High MPO-ANCA titers in remission had still been observed in a substantial number of patients \[30\]. This may be a high risk of relapse implying long-term followup \[31\].
4. Conclusion

The association between Benzylthiouracile and ANCA vasculitis is now well documented. Although its rare occurrence, attention must be given to systemic symptoms such as skin lesion, haematuria or proteinuria. The ANCA must be measured when confronted to systemic manifestation during treatment.

References

[1] MC. Slot, TP. Links, CA Stegeman, and JW. Tervaert, “Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study,” Arthritis Rheum, vol. 53, no. 1, pp. 108–13, 2005.

[2] D. Zimmerman and A. N. Lief, “Thyrotoxicosis in children,” Endocrinology and Metabolism Clinics of North America, vol. 27, no. 1, pp. 109–126, 1998.

[3] S. J. Stankus and N. T. Johnson, “Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure,” Chest, vol. 102, no. 5, pp. 1595–1596, 1992.

[4] J. E. Gunton, J. Stiel, P. Clifton-Bligh, E. Wilmshurst, and A. McElduff, “Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication,” European Journal of Endocrinology, vol. 142, no. 6, pp. 587–590, 2000.

[5] N. Tieulie, H. Du Le Thi, M. Andreu, et al., “Glomerulonéphrite associée aux ANCA secondaire au benzylthiouracile,” Revue de Medecine Interne, vol. 23, pp. 853–856, 2002.

[6] H. Kaaroud, K. Khiari, F. Ben Moussa, S. Barbouch, E. Boussema, and H. Ben Maïz, “Une vasculaire associant une atteinte rénale et pulmonaire au cours d’une maladie de Basedow traitée par le benzylthiouracile,” Revue de Medecine Interne, vol. 23, no. 10, pp. 857–861, 2002.

[7] F. Jarraya, M. Abid, R. Jildi, et al., “Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with benzylthiouracil therapy,” Nephrology Dialysis Transplantation, vol. 18, no. 11, pp. 2421–2423, 2003.

[8] M. Hachicha, T. Kammoun, W. Ben Romdhane, et al., “Vasculitis with renal involvement and antineutrophil cytoplasmic antibodies (ANCA) in a child receiving benzylthiouracil,” Néphrologie & Thérapeutique, vol. 3, no. 4, pp. 147–151, 2007.

[9] K. M. Dolman, R. O. B. Gans, T. J. Vervaet, et al., “Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy,” The Lancet, vol. 342, no. 8872, pp. 651–652, 1993.

[10] B. A. Vogt, Y. Kim, J. C. Jennette, R. J. Falk, B. A. Burke, and A. Sinaiko, “Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children,” Journal of Pediatrics, vol. 124, no. 6, pp. 986–988, 1994.

[11] B. A. Vogt, Y. Kim, J. C. Jennette, R. J. Falk, B. A. Burke, and A. Sinaiko, “Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children,” Journal of Pediatrics, vol. 124, no. 6, pp. 986–988, 1994.

[12] M. Tanemoto, H. Miyakawa, J. Hanai, M. Yago, M. Kitaoka, and S. Uchida, “Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves’ disease: report of three adult cases,” American Journal of Kidney Diseases, vol. 26, no. 5, pp. 774–780, 1995.

[13] D. D’Cruz, A. M. S. Chesser, C. Lightowler, et al., “Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment,” British Journal of Rheumatology, vol. 34, no. 11, pp. 1090–1091, 1995.

[14] Y. Hori, K. Arizono, S. Hara, R. Kawai, M. Hara, and A. Yamada, “Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamaazole therapy,” Nephron, vol. 74, no. 4, pp. 734–735, 1996.

[15] W. G. Couser, “Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy,” American Journal of Kidney Diseases, vol. 11, no. 6, pp. 449–464, 1988.

[16] W. R. Griswold, S. A. Mendoza, W. Johnston, and S. Nichols, “Vasculitis associated with propylthiouracil,” Western Journal of Medicine, vol. 128, no. 6, pp. 543–546, 1978.

[17] F. G. Cassorla, D. N. Finegold, J. S. Parks, et al., “Vasculitis, pulmonary cavitation, and anemia during antithyroid drug therapy,” American Journal of Diseases of Children, vol. 137, no. 2, pp. 118–122, 1983.

[18] Y. Kudoh, S. Kuroda, K. Shimamoto, and O. Iimura, “Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoantibodies,” Clinical Nephrology, vol. 49, no. 1, pp. 41–43, 1997.

[19] J. E. Gunton, J. Stiel, R. J. Caterson, and A. McElduff, “Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature,” The Journal of Clinical Endocrinology & Metabolism, vol. 84, no. 1, pp. 13–16, 1999.

[20] D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 311, no. 21, pp. 1353–1362, 1984.

[21] H. Sato, M. Hattori, M. Fujieda, et al., “High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves’ disease treated with propylthiouracil,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 11, pp. 4270–4273, 2000.

[22] Y. Gao, M.-H. Zhao, X.-H. Guo, G. Xin, Y. Gao, and H.-Y. Wang, “The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism,” Endocrine Research, vol. 30, no. 2, pp. 205–213, 2004.

[23] D. C. C. Lam and R. H. Lindsay, “Accumulation of 2-14C propylthiouracil in human polymorphonuclear leukocytes,” Biochemical Pharmacology, vol. 28, no. 15, pp. 2289–2296, 1979.

[24] E. Lee, M. Hirouchi, M. Hosokawa, H. Sayo, M. Kohno, and K. Kariya, “Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure,” Biochemical Pharmacology, vol. 37, no. 11, pp. 2151–2153, 1988.

[25] A.-M. Haapala, E. Soppi, H. Hytöy, J. Mustonen, and A. Pasternack, “Cross-reactivity between antibodies to thyroid microsomal antigens and myeloperoxidase,” The Lancet, vol. 337, no. 8744, p. 803, 1991.

[26] T. Kitahara, K. Hiromura, A. Maezawa, et al., “Case of propylthiouracil-induced vasculitis associated with antineutrophil cytoplasmic antibody (ANCA): review of literature,” Clinical Nephrology, vol. 47, no. 5, pp. 336–340, 1997.
[28] S. Yuasa, M. Hashimoto, T. Yura, et al., “Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy,” *Nephron*, vol. 73, no. 4, pp. 701–703, 1996.

[29] K. Kanahara, N. Yorioka, C. Nakamura, et al., “Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission,” *Internal Medicine*, vol. 36, no. 11, pp. 841–846, 1997.

[30] S. Otsuka, A. Kinebuchi, H. Tabata, A. Yamakage, and S. Yamazaki, “Myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy,” *British Journal of Dermatology*, vol. 142, no. 4, pp. 828–830, 2000.

[31] L. Harper, P. Cockwell, and C. O. S. Savage, “Case of propylthiouracil-induced ANCA associated small vessel vasculitis,” *Nephrology Dialysis Transplantation*, vol. 13, no. 2, pp. 455–458, 1998.